Research & Literature

Common variants at 10p12.31, 10q21.1 and 13q12.13 are associated with sporadic pituitary adenoma.

Ye Z, Li Z, Wang Y, et al.

Nature genetics 2015; (47(7)):793-7 doi:10.1038/ng.3322.

Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.

Wong A, Eloy JA, Couldwell WT, Liu JK

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2015; (22(10)):1562-7.

Pituitary hyperplasia: an uncommon presentation of a common disease.

Neves CP, Massolt ET, Peeters RP, et al.

Endocrinology, diabetes & metabolism case reports 2015; (2015()):150056 doi:10.1530/EDM-15-0056.

Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.

Tran T, Brophy JM, Suissa S, Renoux C

CNS drugs 2015; (29(12)):985-98 doi:10.1007/s40263-015-0293-4.

A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.

Ceravolo R, Rossi C, Del Prete E, Bonuccelli U

Expert opinion on drug safety 2016; (15(2)):181-98 doi:10.1517/14740338.2016.1130128.

[Current diagnosis and treatment of hyperprolactinemia].

Melgar V, Espinosa E, Sosa E, et al.

Revista medica del Instituto Mexicano del Seguro Social 2016; (54(1)):111-21.

Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.

Takeno A, Yamamoto M, Okazaki K, et al.

The American journal of case reports 2016; (17()):160-4 doi:10.12659/ajcr.894712.

Prolactinoma and pregnancy: From the wish of conception to lactation.

Maiter D

Annales d'endocrinologie 2016; (77(2)):128-34.

A New Method of Using Polyethylene Glycol (PEG) Precipitation of Macroprolactin to Detect Genuine Hyperprolactinemia.

Chen Y, Wang H, Yang W, et al.

Journal of clinical laboratory analysis 2016; (30(6)):1169-1174 doi:10.1002/jcla.21999.

The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS).

Soto-Pedre E, Newey PJ, Bevan JS, et al.

Clinical endocrinology 2017; (86(1)):60-67 doi:10.1111/cen.13156.

Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.

Schwetz V, Librizzi R, Trummer C, et al.

Metabolic brain disease 2017; (32(1)):155-161 doi:10.1007/s11011-016-9882-2.

Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.

Zaidi HA, Cote DJ, Castlen JP, et al.

World neurosurgery 2017; (97()):2-7 doi:10.1016/j.wneu.2016.09.066.

Significance of surgical management for cystic prolactinoma.

Ogiwara T, Horiuchi T, Nagm A, et al.

Pituitary 2017; (20(2)):225-230 doi:10.1007/s11102-016-0766-6.

Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.

Andereggen L, Frey J, Andres RH, et al.

World neurosurgery 2017; (97()):595-602 doi:10.1016/j.wneu.2016.10.059.

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.

Khare S, Lila AR, Patil R, et al.

Indian journal of endocrinology and metabolism 2017; (21(1)):154-159 doi:10.4103/2230-8210.196010.

Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality.

Krogh J, Selmer C, Torp-Pedersen C, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(6)):411-417 doi:10.1055/s-0043-107243.

Hyperprolactinemia in Children with Subclinical Hypothyroidism.

Sharma N, Dutta D, Sharma LK

Journal of clinical research in pediatric endocrinology 2017; (9(4)):350-354 doi:10.4274/jcrpe.4536.

Hyperprolactinaemia in first episode psychosis - A longitudinal assessment.

Lally J, Ajnakina O, Stubbs B, et al.

Schizophrenia research 2017; (189()):117-125 doi:10.1016/j.schres.2017.07.037.

Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas.

Iglesias P, Arcano K, Triviño V, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(9)):654-659 doi:10.1055/s-0043-115645.

Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.

Gamble D, Fairley R, Harvey R, et al.

Therapeutic advances in drug safety 2017; (8(7)):215-229 doi:10.1177/2042098617703647.

Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia.

Kasum M, Orešković S, Čehić E, et al.

Taiwanese journal of obstetrics & gynecology 2017; (56(6)):719-724 doi:10.1016/j.tjog.2017.10.002.

The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

Tugwell-Allsup J, Pritchard AW

Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia.

Abbara A, Clarke SA, Nesbitt A, et al.

Neuroendocrinology 2018; (107(2)):105-113 doi:10.1159/000489264.

Pituitary adenomas in children and young adults.

Krajewski KL, Rotermund R, Flitsch J

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2018; (34(9)):1691-1696 doi:10.1007/s00381-018-3853-3.

Management of antipsychotic-induced hyperprolactinemia.

Tewksbury A, Olander A

The mental health clinician 2016; (6(4)):185-190 doi:10.9740/mhc.2016.07.185.

The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening.

Caputo C, Prior D, Inder WJ

Journal of the Endocrine Society 2018; (2(8)):965-969 doi:10.1210/js.2018-00139.

Work disability and its determinants in patients with pituitary tumor-related disease.

Lobatto DJ, Steffens ANV, Zamanipoor Najafabadi AH, et al.

Pituitary 2018; (21(6)):593-604 doi:10.1007/s11102-018-0913-3.

Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old.

Zhao Y, Jin D, Lian W, et al.

Medicine 2019; (98(6)):e14380 doi:10.1097/MD.0000000000014380.

Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.

Vilar L, Vilar CF, Lyra R, Freitas MDC

Neuroendocrinology 2019; (109(1)):7-19 doi:10.1159/000499694.

Acute Suppression of LH Secretion by Prolactin in Female Mice Is Mediated by Kisspeptin Neurons in the Arcuate Nucleus.

Brown RSE, Khant Aung Z, Phillipps HR, et al.

Endocrinology 2019; (160(5)):1323-1332 doi:10.1210/en.2019-00038.

Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.

Auriemma RS, De Alcubierre D, Pirchio R, et al.

Frontiers in endocrinology 2019; (10()):327 doi:10.3389/fendo.2019.00327.

Interpretation of common endocrine laboratory tests: technical pitfalls, their mechanisms and practical considerations.

Haddad RA, Giacherio D, Barkan AL

Clinical diabetes and endocrinology 2019; (5()):12 doi:10.1186/s40842-019-0086-7.

The Role of Surgery in the Management of Prolactinomas.

Donoho DA, Laws ER

Neurosurgery clinics of North America 2019; (30(4)):509-514 doi:10.1016/j.nec.2019.05.010.

Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study.

Clapham E, Bodén R, Reutfors J, et al.

Acta psychiatrica Scandinavica 2020; (141(1)):74-83 doi:10.1111/acps.13101.

An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.

O'Sullivan SM, Farrant MT, Ogilvie CM, et al.

The Australian & New Zealand journal of obstetrics & gynaecology 2020; (60(3)):405-411 doi:10.1111/ajo.13070.

Medication-induced obstructive uropathy and hyperprolactinemia in a pediatric patient.

Nkansah-Amankra K, Sudhanthar S

Clinical case reports 2019; (7(10)):1928-1931 doi:10.1002/ccr3.2396.

Surgical management considerations in cystic prolactinomas-a single center case series.

Nevzati E, Chatain GP, Carr SB, et al.

Endocrine 2020; (67(1)):58-66 doi:10.1007/s12020-019-02076-8.

Biochemical diagnosis in prolactinomas: some caveats.

Petersenn S

Pituitary 2020; (23(1)):9-15 doi:10.1007/s11102-019-01024-z.

Prolactin response to antipsychotics: An inpatient study.

Dehelean L, Romosan AM, Papava I, et al.

PloS one 2020; (15(2)):e0228648 doi:10.1371/journal.pone.0228648.

Hyperprolactinemia as a prognostic factor for menstrual disorders in female adolescents with advanced chronic kidney disease.

Serret-Montaya J, Zurita-Cruz JN, Villasís-Keever MA, et al.

Pediatric nephrology (Berlin, Germany) 2020; (35(6)):1041-1049 doi:10.1007/s00467-020-04494-7.

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.

Budayr A, Tan TC, Lo JC, et al.

BMC endocrine disorders 2020; (20(1)):25 doi:10.1186/s12902-020-0507-8.

Serial prolactin sampling as a confirmatory test for true hyperprolactinemia.

Francés C, Boix E, Fajardo MT, Gómez-García JM

Endocrinologia, diabetes y nutricion 2020; (67(8)):525-529 doi:10.1016/j.endinu.2019.11.006.

Macroprolactinemia Detection by Magnetically Assisted Polyethylene Glycol Precipitation: Potential for Automation.

Smith T, Stern E, Tan E, et al.

The journal of applied laboratory medicine 2020; (5(3)):494-505 doi:10.1093/jalm/jfaa015.

Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated with Cabergoline.

Astaf'eva L, Shishkina L, Kalinin P, et al.

Asian journal of neurosurgery 2020; (15(2)):385-390 doi:10.4103/ajns.AJNS_16_20.

The Role of Dopamine Agonists in Pituitary Adenomas.

Giraldi EA, Ioachimescu AG

Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

Circulating macroprolactin exhibits molecular heterogeneity and is not exclusively an antibody complex.

Quynh N Nguyen K, Langevin RH, McPhaul MJ, Hashim IA

Clinica chimica acta; international journal of clinical chemistry 2021; (514()):90-95 doi:10.1016/j.cca.2020.12.018.

Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia - A Retrospective Study.

Tsur A, Dreyfuss E, Ness-Abramof R, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(11)):1304-1311 doi:10.4158/EP-2020-0260.

Effect of increased prolactin and psychosocial stress on erectile function.

Fiala L, Lenz J, Sajdlova R

Andrologia 2021; (53(4)):e14009 doi:10.1111/and.14009.

Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

Andereggen L, Frey J, Andres RH, et al.

Scientific reports 2021; (11(1)):5122 doi:10.1038/s41598-021-84606-x.

Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

Bui KT, Kiely BE, Dhillon HM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

Determination of the frequency of hyperprolactinemia-related etiologies and the etiology-specific mean prolactin levels.

Korkmaz FN, Gökçay Canpolat A, Şahin M, Çorapçioğlu D

Minerva endocrinology 2024; (49(3)):243-252 doi:10.23736/S2724-6507.21.03386-8.

Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin.

Hu Y, Ni J, Zhang B, et al.

BMC endocrine disorders 2021; (21(1)):197 doi:10.1186/s12902-021-00861-z.

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine.

Clausen MF, Rørth R, Torp-Pedersen C, et al.

BMC cardiovascular disorders 2021; (21(1)):622 doi:10.1186/s12872-021-02439-y.

Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase.

De Wit LE, Wilting I, Souverein PC, et al.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2022; (58()):30-38 doi:10.1016/j.euroneuro.2022.01.113.

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Mishra R, Konar SK, Shrivastava A, et al.

Indian journal of endocrinology and metabolism 2021; (25(6)):493-506 doi:10.4103/ijem.ijem_338_21.

Increase in Thyrotropin Is Associated with an Increase in Serum Prolactin in Euthyroid Subjects and Patients with Subclinical Hypothyroidism.

Sheikhi V, Heidari Z

Medical journal of the Islamic Republic of Iran 2021; (35()):167 doi:10.47176/mjiri.35.167.

Pituitary Adenoma Incidence, Management Trends, and Long-term Outcomes: A 30-Year Population-Based Analysis.

Graffeo CS, Yagnik KJ, Carlstrom LP, et al.

Mayo Clinic proceedings 2022; (97(10)):1861-1871 doi:10.1016/j.mayocp.2022.03.017.

Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.

Cho A, Vila G, Marik W, et al.

Frontiers in endocrinology 2022; (13()):901385 doi:10.3389/fendo.2022.901385.

The importance of personal documentation for patients living with long-term illness symptoms after pituitary surgery: A Constructivist Grounded Theory study.

Heckemann B, Graf T, Ung EJ, et al.

Health expectations : an international journal of public participation in health care and health policy 2023; (26(1)):226-236 doi:10.1111/hex.13648.

Causes of hyperprolactinaemia in the primary care setting: How to optimise hyperprolactinaemia management.

García Cano AM, Jiménez Mendiguchía L, Rosillo Coronado M, et al.

Endocrinologia, diabetes y nutricion 2022; (69(10)):771-778 doi:10.1016/j.endien.2022.11.019.

[Prolactin and its receptor: From animal models to pituitary pathophysiology].

Begon E, Bernard V

Biologie aujourd'hui 2022; (216(3-4)):105-110 doi:10.1051/jbio/2022019.

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

Scanxiety Conversations on Twitter: Observational Study.

Bui KT, Li Z, Dhillon HM, et al.

JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.

Macroprolactinemia: a mini-review and update on clinical practice.

Koniares K, Benadiva C, Engmann L, et al.

F&S reports 2023; (4(3)):245-250 doi:10.1016/j.xfre.2023.05.005.

Correlations Among Maternal and Infant Factors, Lead Exposure, and Serum Prolactin Levels During Lactation: A Cross-sectional Study in Indonesia.

Wati LR, Sargowo D, Nurseta T, et al.

Journal of preventive medicine and public health = Yebang Uihakhoe chi 2023; (56(5)):422-430 doi:10.3961/jpmph.23.238.

Assessing Bone Mineral Density Using Radiographs of the Hand: A Multicenter Validation.

Burton H, Bodansky D, Silver N, et al.

The Journal of hand surgery 2023; (48(12)):1210-1216 doi:10.1016/j.jhsa.2023.08.009.

[Management of Hyperprolactinemia at the Hôpital du Mali].

Mariko M, Traoré B, Sow DS, et al.

Le Mali medical 2020; (35(2)):26-31.

Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis.

Nagendra L, Dutta D, Mondal S, et al.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(1)):101453 doi:10.1016/j.jocd.2023.101453.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses.

Jiang Q, Li T, Zhao L, et al.

Frontiers in psychiatry 2024; (15()):1337274 doi:10.3389/fpsyt.2024.1337274.

Characterization of bone disease in cystic fibrosis.

Contreras-Bolívar V, Andreo-López MC, Muñoz-Torres M

Medicina clinica 2025; (164(1)):23-29 doi:10.1016/j.medcli.2024.05.014.

A Non-Secreting Pituitary Adenoma That Changed to a Prolactinoma.

Santiago-Vazquez C, Palacios-Paino N, Cordido F

Clinics and practice 2024; (14(4)):1310-1318 doi:10.3390/clinpract14040106.

Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.

Yogeeta F, Rauf SA, Devi M, et al.

Annals of medicine and surgery (2012) 2024; (86(8)):4613-4623 doi:10.1097/MS9.0000000000002308.

Confusion in the interpretation of prolactin levels caused by inappropriately low reference intervals.

Sabogal Piñeros YS, Deckers MML, de Bie P, et al.

Endocrine connections 2024; (13(12)).

Clinical Features and Hormonal Profile of Macroprolactinomas Presenting With the Hook Effect: A Systematic Review.

Mahmoud MM, Haj-Ahmad LM, Sweis NWG, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(2)):215-225 doi:10.1016/j.eprac.2024.11.002.

Etiology, presentation, and outcomes of hyperprolactinemia due to pituitary masses in children and adolescents.

Kilci F, Sarikaya E, Murat NÖ, Deniz A

Endocrine 2025; (88(2)):553-563 doi:10.1007/s12020-025-04176-0.

Cabergoline monotherapy in polycystic ovary syndrome patients with elevated prolactin: a viable option?

Sıgınır A, Bostan H, Saygılı ES, et al.

Endocrine 2025; (89(2)):547-555 doi:10.1007/s12020-025-04279-8.

Artifacts affecting dual-energy X-ray absorptiometry and bone mineral density measurements: a case report and review of the literature.

White K, Shakir MKM, Nguyen C, Hoang TD

Journal of medical case reports 2025; (19(1)):290 doi:10.1186/s13256-025-05353-5.

High-dose Hook Effect in a Case of Giant Prolactinoma Confounded by Acute Kidney Injury.

Lam A, Prosser C, Chik CL

JCEM case reports 2025; (3(8)):luaf136 doi:10.1210/jcemcr/luaf136.

Prolactin impairs erectile function via eNOS suppression independently of testosterone.

Cheng X, Xiao Y, Qiu D, et al.

Toxicology and applied pharmacology 2025; (504()):117532 doi:10.1016/j.taap.2025.117532.

Lipid Profile Differences in Monomeric Hyperprolactinemia, Macroprolactinemia, and Healthy Controls: A Comparative Analysis.

Bahçebaşı S, Gökay F, Şimşek Y

Neuroendocrinology 2025; (115(9)):719-729 doi:10.1159/000547540.

Neuroendocrine Effects of Hyperprolactinemia: Focus on Dopamine and Serotonin Systems.

Kadiri SK, Tiwari P, Khobragade DS, et al.

Endocrine, metabolic & immune disorders drug targets 2025; doi:10.2174/0118715303352625250526073105.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Management outcomes of prolactinoma: a retrospective study from Southern Iraq.

Alobaidy HF, Alidrisi HA, Reman KA, et al.

Journal of medicine and life 2025; (18(9)):869-877 doi:10.25122/jml-2025-0050.

Hyperprolactinemia alters insulin resistance profiles in overweight males.

Rashed HM, El-Ghlban S, Mahfouz MK, Marie YMA

Endocrine regulations 2025; (59(1)):160-166 doi:10.2478/enr-2025-0018.

Clinical outcomes and serum prolactin levels in patients with antipsychotic-induced hyperprolactinemia following different management strategies.

Sangngarm A, Werawattanachai C, Somrak K, et al.

International journal of psychiatry in clinical practice 2026; (30(1)):77-83 doi:10.1080/13651501.2025.2593315.

Unraveling the Cycle: A Scoping Review Exploring the Impact of Antidepressants on the Female Reproductive Cycle.

Weatherly S, Garazi CD, Woldenberg E, et al.

Cureus 2025; (17(11)):e97360 doi:10.7759/cureus.97360.

Study of Clinical Profile and Early Response to Dopamine Agonist Therapy in Patients of Hyperprolactinemia: Experience at a Tertiary Care Centre of Nepal.

Nepal R, Bajracharya MR, Karki BB, et al.

Indian journal of endocrinology and metabolism 2025; (29(6)):667-673 doi:10.4103/ijem.ijem_252_25.

Fertility and pregnancy in patients with prolactinoma.

Stumpf MAM, Queiroz NL, Glezer A

Best practice & research. Clinical endocrinology & metabolism 2026; (40(2)):102081 doi:10.1016/j.beem.2026.102081.

The Spectrum of Serum Prolactin Levels in Patients with Non-Functioning Sellar Masses: A Retrospective Analysis.

Giri S, Suryadevara V, Ramesh AS, et al.

Neurology India 2026; (74(2)):215-220 doi:10.4103/neurol-india.Neurol-India-D-25-00413.

SSRI-Induced Galactorrhea in Adolescents.

Adıgüzel S, Hamoda HM

Journal of child and adolescent psychopharmacology 2026; (36(4)):240-243 doi:10.1177/10445463261436376.

Prolactinoma diagnosis: Clinical, biochemical, and radiological considerations.

Petersenn S

Best practice & research. Clinical endocrinology & metabolism 2026; (40(2)):102103 doi:10.1016/j.beem.2026.102103.

Beyond remission: The unspoken reality of cancer survivorship.

Marcon LR

Explore (New York, N.Y.) 2026; (22(4)):103424 doi:10.1016/j.explore.2026.103424.

Vision Outcomes Following Endoscopic and Microscopic Transsphenoidal Resection of Sellar/Parasellar Lesions - A Systematic Review of the Literature.

Lesha E, Dugan JE, Milton C, et al.

World neurosurgery 2026; (211()):125044 doi:10.1016/j.wneu.2026.125044.

Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia.

Zerbinati L, Cristilli G, Valier B, et al.

Pituitary 2026; (29(3)).

Severe Iatrogenic Tricuspid Regurgitation.

Amaral Pinto I, Macedo D, Rei Neto R

Cureus 2026; (18(5)):e108827 doi:10.7759/cureus.108827.

MRI-Related Claustrophobia: Patient-Reported Experience and Associated Factors in a Makkah Region Cohort.

Aldahery ST, Bushara LA, Alasami RA, et al.

Tomography (Ann Arbor, Mich.) 2026; (12(6)) doi:10.3390/tomography12060077.

Disentangling secretory ambiguity and the limitations of classical thresholds in defining prolactinomas.

Harary M, Thapa M, Harper SD, et al.

Pituitary 2026; (29(4)).